Joseph Negri

TL;DR: Progress in in vitro screening platforms as well as orthotopic and 'orthometastatic' xenograft mouse models has enabled comprehensive characterization of the impact of the tumour microenvironment on therapeutic efficacy, which can hopefully bridge the gap between preclinical studies and clinical trials of anticancer agents.

TL;DR: In this paper, a tumor cell-specific in vitro bioluminescence imaging (CS-BLI) assay was developed to identify stroma-induced chemoresistance in diverse malignancies, including imatinib resistance in leukemic cells.

TL;DR: BEZ235 treatment decreased the amplitude of transcriptional signatures previously associated with myc, ribosome, and proteasome function, as well as high-risk MM and undifferentiated human embryonic stem cells, and indicates that BEZ235 merits clinical testing, alone and in combination with other agents, in multiple myeloma.

TL;DR: These data provide both insights into the molecular mechanisms of antitumor activity of proteasome inhibitors and the rationale for future clinical trials of bortezomib, alone or in combination with conventional chemotherapy, to improve patient outcome in medullary and anaplastic thyroid carcinomas.

TL;DR: The cholesterol-lowering drug lovastatin showed anti-LSC activity in vitro and in an in vivo bone marrow transplantation model, and Mechanistic studies demonstrated that the effect was on target, via inhibition of HMG-CoA reductase.